Low-dose aspirin use and recurrent gout attacks

Annals of the Rheumatic Diseases

Volumn 73, Issue 2, 2014, Pages 385-390

  Zhang, Yuqing ^a   Neogi, Tuhina ^a   Chen, Clara ^b   Chaisson, Christine ^b   Hunter, David J ^c   Choi, Hyon ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; FEMALE; GOUT; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

EID: 84891737348     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202589     Document Type: Article

References (36)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007 2008. Arthritis Rheum 2011;63:3136-41.
2. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7. (Pubitemid 39006641)
3. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403-6. (Pubitemid 35266034)
4. Rott KT, Agudelo CA. Gout. JAMA 2003;289:2857-60.
5. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012;125:679-87.e1.
6. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med 2009;150:405-10.
7. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
8. Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate, and high dosage on the renal mechanisms of excretion of urate in man. J Clin Invest 1959;38:1298-313.
9. Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011;13:R39.
10. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Clev Clin J Med 2008;75(Suppl 5):S13-16.
11. Zhang Y, Chaisson CE, McAlindon T, et al. The online case-crossover study is a novel approach to study triggers for recurrent disease flares. J Clin Epidemiol 2007;60:50-5. (Pubitemid 44873186)
12. Redelmeier DA, Tibshirani RJ. Association between cellular-telephone calls and motor vehicle collisions. N Engl J Med 1997;336:453-8. (Pubitemid 27074355)
13. Albert CM, Mittleman MA, Chae CU, et al. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med 2000;343:1355-61.
14. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001;344:319-26. (Pubitemid 32107639)
15. Peters A, von Klot S, Heier M, et al. Exposure to traffic and the onset of myocardial infarction. N Engl J Med 2004;351:1721-30. (Pubitemid 39383207)
16. Bhaskaran K, Hajat S, Armstrong B, et al. The effects of hourly differences in air pollution on the risk of myocardial infarction: case crossover analysis of the MINAP database. BMJ 2011;343:d5531.
17. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arc Intern Med 2009;169:141-9.
18. Molokhia M, McKeigue P, Curcin V, et al. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PloS One 2008;3:e2522.
19. Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993;329:1677-83. (Pubitemid 23346917)
20. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
21. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8.
22. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306:711-20.
23. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76.
24. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61. (Pubitemid 41781828)
25. Gaffo AL, Schumacher HR, Saag KG, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum 2012;64:1508-17.
26. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among U. S. adults: behavioral risk factor surveillance system. Am J Prev Med 2006;30:74-7. (Pubitemid 43083548)
27. Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest 1959;38:1298-315.
28. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516. (Pubitemid 41379398)
29. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447-52. (Pubitemid 34563537)
30. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997;280:839-45. (Pubitemid 27171347)
31. Manganel M, Roch-Ramel F, Murer H. Sodium-pyrazinoate cotransport in rabbit renal brush border membrane vesicles. Am J Physiol 1985;249:F400-8. (Pubitemid 16225771)
32. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000;43:103-8. (Pubitemid 30368218)
33. Harris M, Bryant LR, Danaher P, et al. Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. J Rheumatol 2000;27:2873-6.
34. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-53.
35. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35.
36. Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs 2010;10:125-41. and Skin Diseases